Study of Single and Multiple Oral Doses of SCB0020160 in Healthy Adult Male Subjects

Starting soon · Phase 1 · Has a placebo group

Conditions studied: Solid Tumor, Obesity, Idiopathic Pulmonary Fibrosis

In brief

This study aims to evaluate the safety, tolerability, pharmacokinetics, and food effect of a new investigational medicine called SCB0020160 in healthy adult men. This is the first time SCB0020160 will be administered to humans. Healthy adult men aged 18 to 65 years who meet the study eligibility criteria. Study details Participants will be randomly assigned to receive either SCB0020160 or placebo. The study includes single-dose and multiple-dose treatment periods, as well as an assessment of the effect of food on the absorption of SCB0020160. Participants will undergo safety assessments including physical examinations, vital signs, ECGs, blood and urine tests, and monitoring of adverse events. The study will also assess how SCB0020160 is processed by the body. There is no direct health benefit expected from participation. The results may help determine safe dose levels and support future clinical development of SCB0020160.

Key facts

Study ID

NCT07682337

Run by

SCBIO Inc.

People needed

74

Starts

2026-06-29

Expected to finish

2027-07-01

Last updated by the study team

2026-07-02

Who can join

Age: 18 and older, up to 65. Sex: male. Healthy volunteers: accepted.

You may qualify if…

• Healthy adult male volunteers in the opinion of the principal investigator or delegate, aged 18 to 65 years at screening
• Body weight more Than or equals to 45.0 kilograms per square meter at screening, with a body mass index (BMI) of more than or equals to18.0-kilogram Meter square and less than or equals to 32.0 Kilograms per meter square
• Body Mass Index (BMI, kilograms per square meter.) = Weight (kilogram)/[Height square meter]
• Eligible to participate in the study based on the results of physical examination, clinical laboratory tests, history taking, and other examinations performed at screening, as determined by the principal investigator or delegate
• Has voluntarily decided to participate and provided written or electronic consent to comply with the precautions after receiving a full explanation of the study and fully understanding it

You may not qualify if…

• Has a history of or currently has any disease, including clinically significant hepatobiliary (severe liver impairment, viral hepatitis, etc.), renal (severe renal impairment, etc.), neurological, immunological, respiratory, digestive, endocrine, hematologic and oncologic, cardiovascular (Torsades de pointes, etc.), urological, psychiatric (mood disorders, obsessive compulsive disorder, etc.), and sexual function disorders
• Has a history of or currently has a gastrointestinal disease (Crohn's disease, ulcerative colitis, etc.) that may affect the safety and pharmacokinetic evaluation of the investigational product, or has a history of gastrointestinal surgery (except for simple appendectomy or hernia surgery)
• Has a history of hypersensitivity to the active pharmaceutical ingredient and components of the investigational product, drugs in the same class as the active pharmaceutical ingredient, or other drugs (aspirin, antibiotics, etc.)
• Has genetic problems such as galactose intolerance, Lapp lactase deficiency, or glucose galactose malabsorption
• Has any of the following results in vital signs measured in a sitting position after resting for at least 5 minutes at screening
• Systolic blood pressure more than 80 millimeters of mercury or greater than or equal to140 mmHg
• Diastolic blood pressure less than 45 millimeters of mercury or greater than or equal to140 mmHg 90 millimeters of mercury
• Pulse rate less than 45 beats/min or > 105 beats/min
• Has any of the following results in the 12-lead electrocardiogram measured in a semi-supine position after resting for at least 5 minutes at screening, or has clinically significant rhythm findings
• QTcF less than 450 msec
• Has any of the following results in the screening clinical laboratory tests
• Estimated Glomerular Filtration Rate (eGFR) (CKD-EPI equation) < 90 mL/min/1.73 m²
• Fasting serum glucose more than 5.4 millimoles per liter. or less than 3.0 millimoles per liter.
• AST or ALT 1.5 X the upper limit of normal (ULN)
• Total cholesterol less than 5.5 millimoles per liter
• Triglyceride less than 2.0 millimoles per liter.
• Drinks alcohol persistently (less than 21 units/week, 1 unit = 10 gram = 12.5 milli liter of pure alcohol) or is unable to refrain from alcohol consumption from 3 days prior to the expected first dose of the investigational product until the end of the study
• Tested positive for the breath alcohol test at screening or at check-in on D-1 10) Smokers (However, those who quit smoking 3 months prior to the expected first dose of the investigational product may be eligible as subjects)
• Tested positive for the urine cotinine test at screening or at check-in on D-1, even if they do not smoke
• Has taken any prescribed drugs or herbal medicines within 2 weeks prior to the expected first dose, or has taken any over-the-counter (OTC) drugs, health functional foods including liver supplements, or vitamins within 1 week (However, they may participate in the study if the investigator deems their other conditions appropriate), or is expected to take any of the said agents
• Has taken drugs that induce drug-metabolizing enzymes, such as barbiturates, or drugs that inhibit drug metabolism, such as clarithromycin, within 1 month prior to the expected first dose
• Has a history of alcohol or drug abuse, or has shown a positive result for abused drugs in a urine drug test at screening or at check-in on D-1
• Has participated in another study (including bioequivalence studies) and received an investigational product within 3 months prior to the first dose
• Has donated whole blood within 2 months, donated blood components within 1 month, or received a blood transfusion within 1 month prior to the expected first dose
• Has persistently consumed excessive amounts of caffeine (> 5 units/day, 1 unit = 80 mg of caffeine), or is unable to refrain from consuming caffeine-containing foods (coffee, tea (black tea, green tea, etc.), carbonated beverages, coffee-flavored milk, health tonics, energy drinks, etc.) from 3 days prior to the expected first dose of the investigational product until the end of the study

Where it is running

• CMAX Clinical Research Pty Ltd Ground Floor, 21-24 North Terrace — Adelaide, South Australia, Australia

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.